SimuGen is a toxicogenomics company originating in Cambridge,  now establishing some operations in  Kuala Lumpur (Malaysia) with the aim of launching the first product from Malaysia within a year. It will be a web-based tool using proprietary dose-response models of gene expression phenotypes from human cell cultures exposed to chemicals. The aim being to help pharma develop safer drugs. This has already attracted significant attention internationally, and the intention is to begin a collaboration with a large pharma company in the near future.